The Multiple Myeloma Daily
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Related Articles
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens – PubMed
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure…
Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium – PubMed
Teclistamab is an anti-CD3xBCMA bispecific antibody approved for use in relapsed/refractory multiple myeloma (MM). We undertook a retrospective study of post-approval, real-world outcomes with teclistamab…
Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström’s Macroglobulinemia – PubMed
Data from our prospectively maintained multicenter database revealed that 8.6% and 3.4% of symptomatic patients with WM developed a SPM and disease transformation, respectively, over…
From CyBorD to Dara-CyBorD: ASCT Utilization Trends in AL Amyloidosis, A 15-Year Analysis – PubMed
This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for AL amyloidosis at Mayo Clinic (2010-2024). We aimed to assess ASCT utilization…
Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era – PubMed
Multiple myeloma (MM) derives from the clonal proliferation of plasma cells, primarily residing in the bone marrow. However, MM cells can disseminate systemically, leading to…
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma – PubMed
BackgroundMultiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical…
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski / cancer, Emiko Sakaida, Kazumoto Shibuya, Marie Morooka, MM, Moeko Ogushi, Myeloma, Myeloma
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series – PubMed
Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.